Table 4 Drug level comparison
From: Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study
|  | Therapeutic drug level (n = 203) | Non-therapeutic drug level (n = 147) | p |
|---|---|---|---|
Antifungal medication | |||
 Voriconazole | 134 (66) | 116 (79) | <0.01 |
 Posaconazole | 69 (34) | 31 (21) |  |
Timing of level | |||
 Pre-steady-state | 72 (35) | 54 (37) | 0.82 |
 Steady-state | 131 (65) | 93 (63) |  |
Male | 98 (48) | 84 (57) | 0.11 |
Weight (kg) (median [IQR]) | 71.0 (60.3–83.0) | 76.2 (59.1–88.3)a | 0.13 |
Age (year) (median [IQR]) | 49 (36–61) | 47 (33–60) | 0.15 |
Race and ethnicity | Â | Â | <0.01 |
 Caucasian | 135 (67) | 89 (61) |  |
 African American | 20 (10) | 6 (4) |  |
 American India or Alaskan native | 4 (2) | 6 (4) |  |
 Asian | 6 (3) | 0 |  |
 Hispanic | 22 (11) | 17 (12) |  |
 Unknown | 16 (8) | 29 (20) |  |
Critically Ill | 88 (43) | 63 (43) | 1.00 |
Transplant status | |||
 Solid organ recipients | 32 (16) | 21 (14) | 0.76 |
 Bone marrow recipients | 55 (27) | 40 (27) | 1.00 |
Comorbidities | |||
 Cystic fibrosis | 18 (9) | 12 (8) | 0.85 |
 Gastrointestinal | 46 (23) | 25 (17) | 0.23 |
Type of infection | |||
 Prophylaxis | 15 (7) | 7 (5) | 0.38 |
 Possible | 33 (16) | 32 (22) |  |
 Probable | 58 (29) | 46 (31) |  |
 Proven | 97 (48) | 62 (42) |  |
Organism (n = 245) | |||
 Candida spp. | 29 (20) | 38 (37) | <0.01 |
 Aspergillus spp. | 48 (33) | 34 (34) |  |
 Mucor | 31 (21) | 7 (7) |  |
 Scedosporium spp. | 18 (12) | 13 (13) |  |
 Cryptococcus | 7 (5) | 0 |  |
 Other | 13 (9) | 9 (9) |  |